PPARG and metabolic disease: This finding opens a window of opportunity for the use of PPARγ, -α, and β/δ agonists, some of which are already in clinical use for metabolic disorders, in chemoprevention of de novo tumor formation in patients at risk.However, the applicability of these compounds as anticancer agents isconfounded by the often confusing findings in mice.